Announced details
Drug discovery and biotechnology, next-generation antibody therapeutics, and multiple disease areas with high unmet medical needs
Toho Holdings invested through the CVC fund “TOHO Ventures.” Toho Holdings is a limited partner in the fund.
Based in Cambridge, Massachusetts, U.S. The representative is Angela Hwang. Established in 2021. Develops functional antibody therapeutics and drug discovery platforms. A next-generation antibody drug discovery company founded by U.S.-based Flagship Pioneering.
Cambridge, Massachusetts, U.S.
The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | MIMIC™, Functional antibody therapeutics and drug discovery platform |
| Counterparty | Metaphore Biotechnologies Inc. |
| Counterparty overview | Based in Cambridge, Massachusetts, U.S. The representative is Angela Hwang. Established in 2021. Develops functional antibody therapeutics and drug discovery platforms. A next-generation antibody drug discovery company founded by U.S.-based Flagship Pioneering. |
| Relationship with the Company | Toho Holdings invested through the CVC fund “TOHO Ventures.” Toho Holdings is a limited partner in the fund. |
| Applicable area | Drug discovery and biotechnology, next-generation antibody therapeutics, and multiple disease areas with high unmet medical needs |
| Location | Cambridge, Massachusetts, U.S. |
| Impact on Business Performance | The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Metaphore has a next-generation platform that uses AI to improve drug discovery productivity, and Toho Holdings valued the company’s function-driven drug discovery approach and advanced AI technology.